Key result
Probenecid derivatives (compounds 8 and 24) demonstrated potent anti-EV activity with values of 2.49/2.09 and 2.59/2.41 μM and good stability in rat serum (half-lives of 48.39 and 60.26 min).
Compounds 8 and 24 are promising probenecid derivatives for the development of new antiviral agents against enterovirus D68 and A71.
AIM: No antiviral medications are currently approved to treat enterovirus (EV)-associated disease or prevent EV infection. METHODS: In this study, a series of probenecid derivatives were designed via a rational strategy and synthesized to obtain more potent anti-EV agents. RESULTS: ) values of 2.49/2.09 and 2.59/2.41 μM, respectively, and revealed a broad inhibition spectrum toward other EV strains, with high selectivity indices. Additionally, compounds 8 and 24 showed good stability in rat serum, with half-lives of 48.39 and 60.26 min, respectively. CONCLUSION: Compounds 8 and 24 are the promising candidates for the development of new agents against EV D68 and A71 viruses.
No takes yet. Share an insight, caveat, or question.
Sethy et al. (2018) studied Enterovirus (EV)-associated disease or EV infection. Probenecid derivatives (compounds 8 and 24) was evaluated on Anti-EV activity and stability in rat serum. Probenecid derivatives (compounds 8 and 24) demonstrated potent anti-EV activity with values of 2.49/2.09 and 2.59/2.41 μM and good stability in rat serum (half-lives of 48.39 and 60.26 min).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: